Legend Biotech Corp (LEGN)
$45.17
Insights on Legend Biotech Corp
Decreasing Revenue
Revenue is down for the last 2 quarters, 96.01M → 79.46M (in $), with an average decrease of 17.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -62.20M → -144.81M (in $), with an average decrease of 132.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 83.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 184.2%
Performance
- $45.13$48.35$45.17
0.09%
Downside
Day's Volatility :6.66%
Upside
6.58%
- $45.17$77.32$45.17
0.0%
Downside
52 Weeks Volatility :41.58%
Upside
41.58%
Returns
| Period | Legend Biotech Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -18.37% | 2.0% | 0.0% |
6 Months | -25.84% | 11.7% | 0.0% |
1 Year | -30.83% | 5.8% | 1.3% |
3 Years | 58.17% | 14.2% | -22.1% |
Highlights
Market Capitalization | 8.6B |
Book Value | $6.88 |
Earnings Per Share (EPS) | -2.94 |
Wall Street Target Price | 86.16 |
Profit Margin | -181.75% |
Operating Margin TTM | -152.34% |
Return On Assets TTM | -17.39% |
Return On Equity TTM | -51.94% |
Revenue TTM | 285.1M |
Revenue Per Share TTM | 1.62 |
Quarterly Revenue Growth YOY | 187.6% |
Gross Profit TTM | -284.0M |
EBITDA | -431.5M |
Diluted Eps TTM | -2.94 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.47 |
EPS Estimate Next Year | -0.62 |
EPS Estimate Current Quarter | -0.83 |
EPS Estimate Next Quarter | -0.62 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 90.75%
Technicals Summary
Sell
Neutral
Buy
Legend Biotech Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Legend Biotech Corp | -16.25% | -25.84% | -30.83% | 58.17% | 28.24% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Legend Biotech Corp | NA | NA | NA | -1.47 | -0.52 | -0.17 | NA | 6.88 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Legend Biotech Corp | Buy | $8.6B | 28.24% | NA | -181.75% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Institutional Holdings
FMR Inc
7.04%T. Rowe Price Associates, Inc.
5.94%RA Capital Management, LLC
3.44%Hillhouse Capital Advisors, Ltd.
3.29%BlackRock Inc
2.89%Capital World Investors
1.31%
Corporate Announcements
Legend Biotech Corp Earnings
Legend Biotech Corp’s price-to-earnings ratio stands at None
Read More
Company Information
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o
Organization | Legend Biotech Corp |
Employees | 1800 |
CEO | Dr. Ying Huang Ph.D. |
Industry | Commercial Services |
Discover More
Marqeta, Inc.
$45.17
-4.81%
Endeavor Group Holdings, Inc.
$45.17
-4.81%
Global X Nasdaq 100 Covered Call Etf
$45.17
-4.81%
Grupo Aeroportuario Del Sureste, Sabdecv
$45.17
-4.81%
Middleby Corp.
$45.17
-4.81%
Dnp Select Income Closed Fund
$45.17
-4.81%
Masonite International Corp
$45.17
-4.81%
Zillow Group, Inc. - Class C Shares
$45.17
-4.81%
Tenet Healthcare Corp.
$45.17
-4.81%